Cao JX, You J, Wu LH, Luo K, Wang ZX. Clinical efficacy analysis of mesenchymal stem cell therapy in patients with COVID-19: A systematic review. World J Clin Cases 2022; 10(27): 9714-9726 [PMID: 36186213 DOI: 10.12998/wjcc.v10.i27.9714]
Corresponding Author of This Article
Zheng-Xu Wang, MD, PhD, Professor, Biotherapy Center, The Seventh Medical Center of People's Liberation Army General Hospital, No. 5 Nanmencang Road, Dongcheng District, Beijing 100700, China. zhxuwang@qq.com
Research Domain of This Article
Biochemistry & Molecular Biology
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Cao JX, You J, Wu LH, Luo K, Wang ZX. Clinical efficacy analysis of mesenchymal stem cell therapy in patients with COVID-19: A systematic review. World J Clin Cases 2022; 10(27): 9714-9726 [PMID: 36186213 DOI: 10.12998/wjcc.v10.i27.9714]
World J Clin Cases. Sep 26, 2022; 10(27): 9714-9726 Published online Sep 26, 2022. doi: 10.12998/wjcc.v10.i27.9714
Clinical efficacy analysis of mesenchymal stem cell therapy in patients with COVID-19: A systematic review
Jun-Xia Cao, Jia You, Li-Hua Wu, Kai Luo, Zheng-Xu Wang
Jun-Xia Cao, Jia You, Li-Hua Wu, Kai Luo, Zheng-Xu Wang, Biotherapy Center, The Seventh Medical Center of People's Liberation Army General Hospital, Beijing 100700, China
Author contributions: Cao JX and Wang ZX conceived and designed the meta-analysis; Cao JX and Wang ZX performed the experiments; Cao JX, Wu LH, You J and Luo K analyzed the data; Cao JX and Wang ZX wrote the paper; All authors have read and approved the manuscript.
Supported byScientific Research Projects in China, No. CLB19J053 and 19SWAQ13.
Conflict-of-interest statement: The authors indicate no potential conflicts of interest.
PRISMA 2009 Checklist statement: The manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zheng-Xu Wang, MD, PhD, Professor, Biotherapy Center, The Seventh Medical Center of People's Liberation Army General Hospital, No. 5 Nanmencang Road, Dongcheng District, Beijing 100700, China. zhxuwang@qq.com
Received: May 6, 2022 Peer-review started: May 6, 2022 First decision: June 11, 2022 Revised: June 26, 2022 Accepted: August 21, 2022 Article in press: August 21, 2022 Published online: September 26, 2022 Processing time: 124 Days and 23.2 Hours
ARTICLE HIGHLIGHTS
Research background
Currently, ongoing trials of mesenchymal stem cell therapies for coronavirus disease 2019 (COVID-19) have been reported.
Research motivation
Whether mesenchymal stem cells have therapeutic efficacy in novel COVID-19 patients.
Research objectives
Clinical trials were published with stem cells therapy in COVID-19 patients.
Research methods
Mantel and Haenszel meta-analysis (Review Manager Version 5.0, Nordic Cochran Centre, Copenhagen) was used for data analysis.
Research results
There was a significant improvement in overall survival (OS) after stem cell therapy; the OS of enrolled patients who received stem cell therapy was 90.3%, whereas that of the control group was 79.8% (P = 0.02).
Research conclusions
Mesenchymal stem cells therapy for COVID-19 patients does not significantly decrease inflammatory markers such as C-reactive protein, D-dimer and interleukin 6, OS is improved.
Research perspectives
Stem cell therapy for COVID-19 patients will become a realistic goal in the foreseeable future.
